Aripiprazole in Body Focused Repetitive Behaviors
Key facts
- Who runs it
- University of Chicago
- Where
- Chicago, United StatesSee the site
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 100 people, planned
- Started
- Jun 2026
- Expected to end
- Dec 2027
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Placebo
- Aripiprazole
- Record updated
- 2 October 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Men and women age ≥18 years
- current DSM-5 trichotillomania or skin picking disorder; and
- Ability to understand and sign the consent form
Who cannot take part
- Stable dose of medications for at least the past 3 months
- Previous treatment with aripiprazole
- Unstable medical illness based on history or clinically significant abnormalities on baseline physical examination
- Past 12-month DSM-5 diagnosis of psychosis, bipolar disorder, mania, or a substance or alcohol use disorder
- Cognitive impairment that interferes with the capacity to understand and self-administer medication or provide written informed consent
- Current pregnancy or lactation, or inadequate contraception in women of childbearing potential
- Subjects considered an immediate suicide risk based on the Columbia Suicide Severity rating Scale (C-SSRS) (www.cssrs.columbia.edu/docs)
- Illegal substance use based on urine toxicology screening
Where in United States
- University of ChicagoChicago, United StatesContact: Madison Collins, BANot yet recruiting
About the trial
What the trial wants to find out
This study is 6 weeks long and involves subjects taking aripiprazole or placebo. If they are randomly assigned to the aripiprazole arm and are eligible to participate in the study, they will begin by taking 5mg once daily of aripiprazole for two weeks, then 10mg once daily for the remaining three weeks. Efficacy and safety measures will be performed at each visit. Participants will be randomized to receive either aripiprazole or placebo on a 1:1 basis. This blinding will be maintained by the IDS pharmacy at the University of Chicago.
The 2 groups in the trial
- PlaceboPlacebo, for comparison
5mg once daily of placebo for three weeks, then 10mg once daily for the remaining three weeks.
- AripiprazoleTreatment being tested
5mg once daily of aripiprazole for three weeks, then 10mg once daily for the remaining three weeks.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Double-Blind, Placebo Controlled Study of Aripiprazole in Body Focused Repetitive Behaviors
- Record updated
- 2 October 2025